Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NW-301V in Advanced Solid Tumors Harboring KRAS G12V Mutations
NCT07875920Phase 1Not yet recruiting
- Sponsor
- Neowise Biotechnology
- Start
- Oct 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NW-301V in solid tumor, pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma and 1 more, sponsored by Neowise Biotechnology. Primary endpoints: Safety and tolerability of NW-301V at 2 years, Maximum Tolerated Dose at 28 days and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
NW-301V
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)colorectal adenocarcinomalung adenocarcinoma
Beyond the preview
Go deeper on NCT07875920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875920.